Home » Stocks » OSMT

Osmotica Pharmaceuticals PLC (OSMT)

Stock Price: $3.31 USD -0.02 (-0.60%)
Updated Jul 29, 2021 12:22 PM EDT - Market open
Market Cap 206.97M
Revenue (ttm) 153.12M
Net Income (ttm) -86.12M
Shares Out 62.68M
EPS (ttm) -1.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $3.31
Previous Close $3.33
Change ($) -0.02
Change (%) -0.60%
Day's Open 3.33
Day's Range 3.27 - 3.35
Day's Volume 41,379
52-Week Range 2.70 - 6.49

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BRIDGEWATER, NJ, June 30, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that J. Aaron ...

4 weeks ago - GlobeNewsWire

Reddit penny stocks continue to make big waves; are these 9 on your watchlist? The post Best Penny Stocks on Reddit to Buy Now?

Other stocks mentioned: AUUD, CEI, LKCO, SHIP, GRIL, GROM, SB ...
1 month ago - PennyStocks

Osmotica Pharmaceuticals plc (NASDAQ: OSMT) has agreed to sell its portfolio of legacy products and Georgia manufacturing facility, for up to $170 million, to Alora Pharmaceuticals LLC. Osmotica will re...

1 month ago - Benzinga

Osmotica will receive a $110 million upfront cash payment, with the potential to receive up to $60 million in additional milestone payments Alora will acquire manufacturing operations in Marietta, Georg...

1 month ago - GlobeNewsWire

BRIDGEWATER, N.J., June 18, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced results of t...

1 month ago - GlobeNewsWire

BRIDGEWATER, N.J., May 25, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Ma...

2 months ago - GlobeNewsWire

OSMOTICA PHARM (OSMT) delivered earnings and revenue surprises of 34.78% and -25.38%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

BRIDGEWATER, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Ma...

2 months ago - GlobeNewsWire

Annual Awards Program Recognizes Outstanding Health & Medical Technology Products and Companies Annual Awards Program Recognizes Outstanding Health & Medical Technology Products and Companies

2 months ago - GlobeNewsWire

BRIDGEWATER, N.J., May 07, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Comp...

2 months ago - GlobeNewsWire

OSMOTICA PHARM (OSMT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

New York, New York--(Newsfile Corp. - April 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (NASDAQ: OSMT). Such in...

3 months ago - Newsfile Corp

Shares of Osmotica Pharmaceuticals (NASDAQ:OSMT) decreased after the company reported Q4 results. Quarterly Results Earnings per share decreased 1566.67% over the past year to ($0.88), which missed the ...

3 months ago - Benzinga

Fourth quarter and full year 2020 total revenue of $34.5 million and $177.9 million, respectively

3 months ago - GlobeNewsWire

BRIDGEWATER, N.J., March 24, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Co...

4 months ago - GlobeNewsWire

BRIDGEWATER, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian ...

4 months ago - GlobeNewsWire

BRIDGEWATER, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian M...

5 months ago - GlobeNewsWire

BRIDGEWATER, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Ap9

5 months ago - GlobeNewsWire

BRIDGEWATER, N.J., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Ap9

6 months ago - GlobeNewsWire

BRIDGEWATER, N.J., Jan. 27, 2021 (GLOBE NEWSWIRE) -- fAp9

6 months ago - GlobeNewsWire

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

6 months ago - GlobeNewsWire

While most of Wall Street focuses on large- and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: KGC, NDLS, TACO, WIMI
6 months ago - 24/7 Wall Street

One of the company's pipeline candidates ran into a regulatory hurdle.

6 months ago - The Motley Fool

BRIDGEWATER, N.J., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has issu...

6 months ago - GlobeNewsWire

Osmotica Pharmaceuticals (NASDAQ: OSMT) shares were trading higher Monday in anticipation of a ruling by the FDA on the company's New Drug Application for Arbaclofen ER in patients with multiple scleros...

Other stocks mentioned: AYTU, KNTE, MYOV
7 months ago - Benzinga

Adamas to acquire global rights to OSMOLEX ER® for $7.5 million

7 months ago - GlobeNewsWire

-- Addition of Dr. Raymond Douglas, M.D., PhD, further enhances RVL's commitment to advancing the clinical and scientific platform supporting Upneeq -- -- Addition of Dr. Raymond Douglas, M.D., PhD, fur...

8 months ago - GlobeNewsWire

BRIDGEWATER, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian M...

8 months ago - GlobeNewsWire

Osmotica Pharmaceuticals' (OSMT) CEO Brian Markison on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Shares of Osmotica Pharmaceuticals (NASDAQ:OSMT) rose 4.4% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share decreased 148.28% year over year to ($0.14)...

8 months ago - Benzinga

Third quarter 2020 total revenue of $57.2 million

8 months ago - GlobeNewsWire

BRIDGEWATER, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Com...

8 months ago - GlobeNewsWire

-- Phase 3 trials showed UPNEEQ was associated with positive outcomes after instillation on days 1 and 14 and was well-tolerated, demonstrating its potential promise for the treatment of acquired ptosis...

9 months ago - GlobeNewsWire

BRIDGEWATER, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Bria...

10 months ago - GlobeNewsWire

Osmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

OSMOTICA PHARM (OSMT) delivered earnings and revenue surprises of 0.00% and -2.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Shares of Osmotica Pharmaceuticals (NASDAQ:OSMT) decreased 4.46% in after-market trading after the company reported Q2 results.

11 months ago - Benzinga

Second quarter 2020 total revenue of $37.5 million

11 months ago - GlobeNewsWire

-Company to discuss launch plans for Upneeq and will be joined by Dr. Derek Cunningham, OD, FAAO- -Company to discuss launch plans for Upneeq and will be joined by Dr. Derek Cunningham, OD, FAAO-

11 months ago - GlobeNewsWire

OSMOTICA PHARM (OSMT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

11 months ago - Zacks Investment Research

OSAKA, Japan and BRIDGEWATER, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd (hereinafter, Santen) and RVL Pharmaceuticals, Inc., a subsidiary of Osmotica Pharmaceuticals plc (...

1 year ago - GlobeNewsWire

BRIDGEWATER, N.J., July 20, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) through its subsidiary Osmotica Pharmaceutical US LLC (“Osmotica” or the “Company”), a fully integrated...

1 year ago - GlobeNewsWire

The company announced the pricing of a public offering of common stock.

1 year ago - The Motley Fool

BRIDGEWATER, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today the pricin...

1 year ago - GlobeNewsWire

BRIDGEWATER, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today the commen...

1 year ago - GlobeNewsWire

Osmotica Pharmaceuticals (NASDAQ: OSMT) surged Friday, ending the day up 25.3% to close at $8.77 per share.

1 year ago - Benzinga

One of the company’s promising products was approved by the FDA.

1 year ago - The Motley Fool

-- First and only FDA-approved pharmacologic treatment for acquired blepharoptosis -- -- Company to host Investor Call at 10:00 a.m. ET today to discuss approval, key elements of the clinical data and ...

1 year ago - GlobeNewsWire

-- Submission based on world’s largest database of patients treated for spasticity associated with Multiple Sclerosis -- -- Demonstrated efficacy, tolerability and one-year safety results on 80 mg/day --

1 year ago - GlobeNewsWire

Osmotica Pharmaceuticals (OSMT) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

About OSMT

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase... [Read more...]

Industry
Biotechnology
Stock Exchange
NASDAQ
Ticker Symbol
OSMT
Full Company Profile

Financial Performance

In 2020, OSMT's revenue was $177.88 million, a decrease of -25.89% compared to the previous year's $240.03 million. Losses were -$79.59 million, -70.62% less than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for OSMT stock is "Buy." The 12-month stock price forecast is 7.50, which is an increase of 126.59% from the latest price.

Price Target
$7.50
(126.59% upside)
Analyst Consensus: Buy